Purchase this article with an account.
Young Joo Park, Youngmi Park, Soyeon Ahn, Seong Jun Byun, Sang Jun Park; Utility values for central vision with unilateral and bilateral ocular conditions for Korean population. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4464.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To identify utility values associated with unilateral and bilateral ocular conditions for Korean population
A total of 28359 participants representing civilian, non-institutionalized Korean population were included from the Korean National Health and Nutrition Examination Survey from 2008 to 2012. An association between Korean version of EuroQol-5D-3L and central vision of unilateral and bilateral ocular conditions were explored by calculating utility values. The utility values were modeled by weighted regression analysis and the robustness was determined by R-square value.
The mean utility value for logMAR 0.0 (20/20, Snellen equivalent) of the better-seeing eye’s visual acuity (BEVA) was 0.9655, and the values were gradually decreased to 0.7800 at the logMAR 0.4 (20/50) of BEVA. The mean utility values from logMAR 0.5 (20/63) to logMAR 1.0 (20/200) were variable. The best fit model by weighted regression analysis was determined as 2nd-order regression equation with R-square value 0.0865. The utility values according to the difference between BEVA and worse-seeing eye’s visual acuity (WEVA) did not largely differ from the utility values accoding to BEVA in the logMAR 0 (20/20) to logMAR 0.2 (20/32) of BEVA, or in logMAR 0.9 (20/160) to logMAR 1.0 (20/200) of BEVA, although there was a variety of distribution in utility values according to the difference between BEVA and WEVA in logMAR 0.3 (20/40) to logMAR 0.8 (20/125). Interaction tendency of the chronic disease state on the association of BEVA and quality of life was shown as graphs.
These utilities can be used for calculating quality-adjusted life-year gains in cost-utility analysis. BEVA is a important determinant for quality of life, but WEVA can affect the quality of life in logMAR 0.3 (20/40) to logMAR 0.8 (20/125) of BEVA.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only